199
Participants
Start Date
January 31, 2015
Primary Completion Date
April 30, 2016
Study Completion Date
April 30, 2016
Placebo (for Alirocumab)
Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
Alirocumab
Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
Lipid-Modifying Therapy (LMT)
Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
Investigational Site Number 158001, Taipei
Investigational Site Number 158003, Taipei
Investigational Site Number 158002, Taipei
Investigational Site Number 158007, Changhua
Investigational Site Number 158008, Tainan City
Investigational Site Number 158009, Tainan Hsien
Investigational Site Number 158011, Kaohsiung City
Investigational Site Number 158010, Kaohsiung City
Investigational Site Number 158005, Hsinchu
Investigational Site Number 410001, Anyang
Investigational Site Number 410009, Anyang-si
Investigational Site Number 410017, Busan
Investigational Site Number 410007, Busan
Investigational Site Number 410002, Daegu
Investigational Site Number 410011, Goyang-si
Investigational Site Number 410003, Gwangju
Investigational Site Number 410012, Incheon
Investigational Site Number 410018, Jeonju
Investigational Site Number 410006, Seoul
Investigational Site Number 410004, Seoul
Investigational Site Number 410015, Seoul
Investigational Site Number 410008, Seoul
Investigational Site Number 410005, Seoul
Investigational Site Number 410010, Seoul
Investigational Site Number 410013, Ulsan
Investigational Site Number 158006, Taichung
Investigational Site Number 158004, Taoyuan Hsien
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY